Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Besilesomab→

Besilesomab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
537694-98-7
Molecular formula
Not available
Molecular weight
Not available
Drug class
Murine monoclonal anti-NCA-95 antibodydiagnostic radiopharmaceutical precursor (99mTc-labelled kit)
Mechanism of action
Binds the NCA-95 antigen on granulocytes. Following radiolabelling with technetium-99m, the antibody carries radioactivity to granulocyte-rich sites of infection or inflammation, allowing scintigraphic localisation.
Indications / reported uses
  • Diagnostic scintigraphic imaging, alongside other appropriate imaging modalities, to locate peripheral bone infection/inflammation in adults with suspected osteomyelitis; not for diagnosing diabetic-foot infection
View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Besilesomab Environmental Risk Assessment (ERA) (the Besilesomab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.